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Encephalitis caused by Japanese encephalitis virus (JEV) is a leading cause of viral 
encephalitis of children less than 15 years old in Asia including Thailand. The virus is 
transmitted to human by several species of culicine mosquitoes including Culex 
tritaeniorhynchus, Culex gelidus, and Culex vishnui. The natural cycle occurs as a zoonotic cycle 
of which either pigs or birds serve as vertebrate amplifying host and man appears to be 
accidental hosts. In addition to human disease, JEV produces abortion and neonatal death in 
pigs and death in horses, which are economically important in the area where Japanese 
encephalitis occurs. Currently the specific drug for treatment of Japanese encephalitis is not 
available. The promising strategy for the prevention of this disease is vaccination together 
with efficient mosquito control, protection of the amplifying hosts, and prevention human 
from mosquito biting. Thus, the prevention and control of this disease is a challenged issue. 
The development of a vaccine that would induce rapid protection in people and animals is 
currently remained as an important issue. New generation of safe chimeric viruses that are 
unable to infect mosquitoes is currently ongoing in the development and preclinical studies. 
This would be a major step toward production of live-attenuated vaccine that is safer for the 
environment and would minimize the risk for vaccine-born outbreaks as reported in 1970s 
for TC-83 vaccine. However, additional efficacy trials in nonhuman primates are required 
to confirm the protective response for some of the candidates and for initiation of 
potential clinical trials. Some of the recent experimental data indicates that the immune 
response against Venezuelan Equine Encephalitis virus (VEEV) needed to control the 
brain infection may differ from the one required to control the peripheral infection. 
Therefore, vaccines that protect against the natural infection may differ in the future from 
those that are supposed to protect against high-dose air-borne challenge and may be more 
attenuated. Our group is also trying to use the most recent pathogenesis data to design a 
therapeutic vaccine that would reverse already established encephalitis and help clear the 
virus from the brain. 
Plasmid DNA-based vaccination strategies have become an active area of research over the 
past decade due to their potential to produce safer and cheaper vaccines. These vaccines 
could be delivered to recipients by intra-muscular (IM) injection or intra-dermal (ID) 






predominantly T helper 1 (Th1) immune responses, while T helper 2 (Th2) type immune 
responses are generated following the ID delivery. The isotypes of antibodies and the types 
of cytokines induced by the two methods differ and this could have bearing on the efficacy 
of the vaccine candidate.  
Attempts have been made to construct the plasmid DNA vaccine against JEV by trying to 
include JEV e gene in the plasmid DNA. It has been shown that these plasmids are capable 
of synthesizing JEV premembrane (prM) and E proteins, which have been evaluated in mice. 
Both forms of E protein however generated JEV neutralizing antibodies that provided 
significant protection to mice against lethal JEV challenge. 
In pre-clinical studies, after evaluation in rodent models, nonhuman primates are usually 
the models of choice as they provide a robust system for evaluation of vaccine candidates. 
The Old World monkeys have predominantly been used in these types of studies with 
rhesus (Macaca mulatta) and cynomolgus (Macaca fascicularis) monkeys being most popularly 
used for evaluation of vaccine candidates against various infectious diseases, including 
those caused by Flaviviruses. It has been shown that the immunogenicity of premembrane-
envelop proteins (pMEa and pMEs) delivered intramuscularly (IM) or intradermally (ID) in 
rhesus monkeys resulted in the DNA immunization induced protective levels of JEV 
neutralizing antibodies and generated robust memory that led to a rapid and sustained 
anamnestic response in monkeys sham challenged with mouse brain-grown, formaldehyde 
inactivated commercial vaccine. Several JEV proteins were evaluated in the DNA vaccine 
modality for their ability to induce protective immunity in the murine system. These include 
plasmids could express non-structural protein 1 (NS1), E or prM and E proteins of JEV. It 
was shown that variable degree of efficacy in murine model systems with plasmids 
expressing prM and E proteins conferring high degree of protection of mice against lethal 
JEV challenge, largely due to their ability to induce JEV neutralizing antibodies. Two 
plasmids could express prM protein along with full-length anchored E or truncated 
secretory E protein, while both plasmids induced JEV neutralizing antibodies in mice. To 
achieve this, efforts are underway to further enhance the immunogenicity of JE DNA 
candidate vaccine. 
Another alternative approach for controlling Japanese encephalitis is the reduction in 
mosquito vector population. It has been shown that the JEV can cause a long-lasting viremic 
phase in amplifying hosts. The virus can cause infection in pigs with the viremic phase last 
for 28 days, whereas the viremic phase in infected birds last for 4-5 days with a very high 
virus titer, about 105 pfu/ml in a house sparrow. These long lasting viremia in amplifying 
hosts provide ample opportunities for the susceptible mosquito vectors to become infected 
after feeding on them. Therefore, if we can reduce the population of mosquito vectors, the 
chances are possible to control the epidemic of JEV in the endemic areas. The slow-release 
formulations of products made from microbial insecticides, i.e., Bacillus sphaericus, and 
Bacillus thuringiensis var. israelensis, have been used in field trials against certain species of 
mosquito larvae especially Culex quiquefasciatus, with a satisfactory result. However, it is 
very difficult to apply the aforementioned formulations of microbial insecticides’ products 
in the breeding places of the mosquito vectors, because the mosquito larvae of Culex species 
are filter feeder, which feed on the surface of the water. All larvae of the mosquito vector 
species are found in polluted water. It has been shown that the effectiveness of microbial 
insecticides’ products is not reached a satisfactory result. Efforts on the development of 
microbial insecticides for biological control of mosquito vector are underway in parallel 
with the recent advances in biotechnology 
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2. Natural cycle of Japanese encephalitis virus 
Japanese encephalitis virus (JEV) has long been recognized as a member of viruses, which 
has been classified in the genus Flavivirus of the family Flaviviridae. The natural transmission 
cycles involving avian or swine reservoir hosts, where culicine mosquitoes serve as vectors. 
The virus has ability to cause fatal infections in horses, and is transmitted to human by 
several species of culicine mosquitoes including Culex tritaeniorhynchus, Culex gelidus, and 
Culex vishnui in Thailand. In general, the natural cycle occurs as a zoonotic cycle of which 
either pigs or birds serve as vertebrate amplifying host and man appears to be accidental hosts. 
In addition to human disease, JEV produces abortion and neonatal death in pigs and death in 
horses, which are economically important in the area where Japanese encephalitis occurs. 
In general, a three-way relationship between virus, host and environment that has evolved 
over millions of years, is considered as a basic requirement of a given mosquito-borne 
viruses to occupy a particular ecological niche. A certain virus is confined perhaps to the 
forests of one continent; it infects one or a small number of species of mosquitoes that 
habitually feed off one or a few species of vertebrate. Any given species of vertebrate that 
serves as an efficient host, it must be abundant, must reproduce rapidly, and above all 
musts maintain a high level of viremia for an adequate period. In its turn, any species of 
mosquitoes that will serve as an efficient vector, must have a sufficiently low threshold of 
infection by that virus, must then carry and shed the virus in its salivary secretions for life, 
but not be adversely affected by it, and must have a distribution, flight range longevity, and 
biting habits well adapted to the habits and habitats of its principal vertebrate host. Hence 
the virus flourishes indefinitely in a state of peaceful coexistence with vertebrate and 
mosquito host in which no one-get hurt. The troubles arise when the virus moves beyond 
this enzootic cycle. 
2.1 Virus properties 
It is quite interesting to learn how JEV replicates itself and continually circulates in nature. 
Japanese encephalitis virus, a 40- to 50-nm-sized enveloped virus, has a single positive-
strand RNA genome. The RNA genome contains three structural (capsid, pre-M, and 
envelope) and seven nonstructural (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5) proteins 
(Chambers et al., 1999). An inactive vaccine is available against JEV, but multiple doses are 
required to confer protective immunity and some pathogenic side effects have been reported 
(Ku et al., 1994). There are no specific effective drugs available to treat Japanese encephalitis 
virus infections.  
Four basic criteria in incriminating the mosquitoes as a vector of JEV have been met by Culex 
tritaeniorhynchus which including, i.e., isolation of JEV from naturally infected mosquitoes, 
laboratory demonstration of the ability of the mosquitoes to become infected by feeding on a 
viremic host, laboratory demonstration of the ability of these infected mosquitoes to 
transmit the virus during blood feeding, and evidence of blood feeding contact between the 
suspected mosquito vector and suspected vertebrate hosts under natural conditions. All 
evidences supported these criteria were demonstrated in Thailand (Grossman et al., 1974). 
2.2 Virus changes 
There are some evidences that the virus itself changes in nature during its replication cycles. 






status by their ability to produce and maintain a high titer of virus throughout the life of the 
vector. The replication of virus does not cause a cytopathic change in the salivary glands 
(Takahashi & Suzuki, 1979). This event is very important for the virus itself to survive in 
nature. In addition to the ability of JEV that can replicate in various kinds of hosts and 
vectors, JEV also obtains its envelope from the modification of host cell membrane during 
the budding process. Thus, it has been postulated that genetic variation of JEV in nature 
may occur following several replication cycle in different kind of vectors and hosts. This 
hypothesis has been verified by the comparison of short nucleotide sequences of JEV isolates 
from various countries, and demonstrated that the similarity of the JEV isolates can be 
segregated into three groups, i.e., group I in which they were recovered from northern 
Thailand and Cambodia, group II were those isolates that recovered from southern 
Thailand, Malaysia, Sarawak and Indonesia, and group III were those isolates that recovered 
from Japan, China, Taiwan, the Philippines, Sri Lanka, India and Nepal (Chen et al., 1990). 
This finding provides insight into the evolution, transmission and possibly, pathogenesis of 
JEV. The possibility of virus changes still exists. Once the virus has been changed, it can lead 
to new epidemic in an appropriate ecological niche because it can escape from herd 
immunity, which developed against the previous form of the virus. 
Mosquito-borne disease usually occurs when unnatural hosts become involved. When man 
lives in regions in which a particular mosquito-borne virus is enzootic he is vulnerable to 
infection and a few of those infected may suffer severe, even lethal, disease. Visitors such as 
tourists, soldiers, or forest workers are even more vulnerable as, unlike the indigenous 
population, they will not have acquired immunity from subclinical infection in childhood. 
In tropical countries where the mosquito vector is plentiful year round, the risk is always 
present and human disease is endemic. In regions subject to monsoonal rains, epidemics of 
mosquito-borne diseases may occur toward the end of the wet season due to the abundance 
of mosquito population. In some temperate countries, and particularly in arid areas, human 
epidemics of mosquito-borne disease occur following periods of exceptionally heavy rain. A 
different species of mosquito, with anthropophilic habits, may become involved in 
transmission of the virus to humans, and may then maintain the virus in a man-mosquito-
man cycle without the intervention of the natural vertebrate or invertebrate host. 
2.3 Infections and pathogenesis 
The infection in man is usually initiated by the viruses are introduced through the skin by 
the bite of a mosquito vector. The virus is replicated in cytoplasm and maturation with 
budding process and the mature virions are released into cytoplasmic vesicles. The mature 
virions gain the envelope by modified the cell membrane of the host with the insertion of 
specific glycoprotein into the membrane. The mature virions inside cytoplasmic vesicles are 
easily released from the infected cells. Virions that enter the lymphatic capillaries are carried 
to the local lymph nodes, which act as filters. As they enter, virions are exposed to the 
macrophages lining the marginal sinus and are usually engulfed. They may be inactivated 
and digested and their antigens presented to the underlining lymphoid cells in such a way 
that the immune response is initiated. However, JEV can multiply in the macrophages which 
some virions may pass straight through the lymph node and eventually enter the blood 
stream. Since the macrophage and lymphocytes in the lymph node are constantly circulating 
in the lymph and blood vascular systems, virus may be passively transported around the body 
in these cells. The important target organ for JEV is CNS (White & Fenner, 1984).  
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The degree of severity of the disease in man caused by this virus is rather depended on the 
degree of neuronal destruction. Case fatality rates average about 10 – 20 % and survivors are 
often with permanent neurological sequelae such as mental retardation, epilepsy, paralysis, 
deafness, and blindness (White & Fenner, 1984). 
The first know outbreak of JEV in Thailand occurred in 1964 in Phitsanulok Province of 
northern part of the country. Another outbreak was reported in 1969 in Chiang Mai 
Province with more than 650 cases and mortality rate of 27 %. Sporadic outbreak occurred in 
the following year in the same area and spread to adjacent provinces (Sangkawibha et al., 
1982). It is of interest that the year 1964 was also a year in which very large JE epidemics 
occurred in Japan and Korea (Kono & Kim, 1969). Hospital records in Chiang Mai Province 
reveal that periodic rainy season outbreaks of febrile encephalitis, probably caused by JEV, 
have occurred in northern Thailand since at least 1962 (Grossman et al., 1973).  
Human JEV infections, however, are infrequent events. Incidence rates of clinical JEV 
infections in Thailand with recurrent JE epidemics have usually been between one and 10, 
and rarely higher than 30 per 100,000 population per year (Wang, 1964; Chen et al., 1990). 
The inapparent JEV infections occur more frequently, but, in the relatively sparse data 
available, infection rates of only about five per cent have been found in the few groups of 
people (mostly schoolchildren) who have been followed serologically through an epidemic 
season (Southam, 1956; Scherer et al., 1959a; Wang, 1964). 
2.4 Vector capability and transmission of virus 
The role of vector in maintaining viruses in nature is very critical and important for the 
virus. The most extensive epidemiologic studies of JEV have been carried out in northern 
temperate areas, where mosquitoes are not active in the winter. The virus reappears in the 
same locality year after year, and consequently considerable effort has been devoted to 
determining how the virus survives when its vectors are inactive. In fact, JEV had been 
recovered from adult mosquitoes reared from field-collected larvae and never exposed to 
JEV in the laboratory (Mitamura et al., 1939). This finding and the reports of transovarial 
transmission by mosquitoes of La Crosse virus (Watts et al., 1973), and other viruses have 
led to the experimental studies of transovarial transmission of JEV by mosquitoes. It was 
shown that such transmission could be demonstrated by Aedes albopictus and Aedes togoi in 
1978 (Rosen et al., 1978). Thus, transovarial transmission may serve as one of alternative 
ways for JEV survives the winter in the northern temperate zone. But transovarial 
transmission may not be necessary for JEV in tropical areas where mosquito vectors and 
amplifying hosts are abundant all year round. 
For vector roles of JEV, it has been shown that a small number of closely related species of 
Culex mosquitoes serve as vectors. It is very interesting to note that some species of 
mosquitoes are not only serving as vectors for the virus transmission, they may also serve as 
an important tool in epidemiological studies. It is important to appreciate the difficulties 
involved in this sort of epidemiological detective work. Mosquito-borne viruses are 
generally so difficult to isolate from man, thus field-collected mosquitoes are the important 
specimens for virus isolation attempts and in fact most of them are originally discovered in 
mosquitoes collected from tropical forests or from “sentinel” animals left overnight in 
mosquito-infested areas. However, only certain species of Culex mosquitoes can serve as 
vectors for JE virus. Several factors may play an important role for species-specific activity 






2.5 The relationships between virus and mosquito 
The capacity of a vector to transmit high titers of virus is an important factor in the vector 
potential of the species in addition to the susceptibility of the vector to the virus. In this 
sense, concentration of JEV as high as 104.2 in the saliva of Culex tritaeniorhynchus for 
prolonged incubation periods demonstrate the high vector potential of this mosquito 
(Takahashi, 1976). It has been shown that when mosquitoes are maintained under autumn 
or winter conditions virus concentrations of whole mosquitoes are lower than in those 
exposed to summer conditions, and the virus antigen is restricted to the midgut (Kay et al., 
1989).   
Culex tritaeniorhynchus is known as the principal vector of JEV in many countries, i.e., Japan 
(Buescher et al., 1959), Okinawa (Hurlburt & Nibley, 1964), and Thailand (Simasathien et al., 
1972). A complete study on vectors of JEV in Thailand was done in Chiang Mai Valley. It 
was shown that peaks in the population densities of Culex fuscocephala, Culex gelidus and 
Culex tritaeniorhynchus, as measured by weekly light-trap collections, occurred during the 
rainy season (April-October) at the time of human and animal JEV infections. Analysis of 
mosquito blood meals indicated that, while the three vector species fed on humans and a 
variety of domestic animals, their most frequent hosts were buffalo and cattle. Feeding 
activity by the three vector species began after dark and was maintained throughout the 
night. These mosquitoes were predominantly exophilic, and very few were collected inside 
houses. All these findings suggest that the three incriminated vector species act principally 
to maintain a cycle of JEV infection in domestic animal populations that only occasionally 
involves humans in the Chiang Mai Valley (Gould et al., 1974).  
2.6 Man as carrier 
Man when bitten by an infected mosquitoes, develops a viremia about the end of the 
incubation period (usually about 5 to 6 days), be remains infective for other Culex 
mosquitoes biting him during the first 4 or 5 days of illness. The new mosquito after 
ingesting virus can transmit beginning 8 to 10 or more days later and for as long as it lives. 
From this we may assume that a person infected with a JEV in Bangkok may fly to Songkhla 
or other cities or neighboring countries before he is ill, then become ill there and be a source 
of virus for the local Culex mosquitoes, which 10 days later pass it on locally and soon a new 
epidemic center occurs. From here it is carried up river by boat, or elsewhere by train, car or 
oxcart to other smaller cities and towns. However, the trouble with all of these assumptions 
applied of Japanese encephalitides spread is that JEV is known to be present endemically in all 
of these places for a long time, being carried about originally in this same way before these 
epidemics of JE started. Something new must have intervened. However, once it is introduced 
as viremia in a returning traveler, animal or bird, including migrants, for example, or in an 
infected insect vector accidentally imported by airplane, ship or car, they probably would not 
become established successfully in the country. Eventually, after the virus is landed in a 
suitable habitat, they could become established and might even become endemic. 
2.7 Vertebrate hosts 
Another important factor in natural cycle of JEV is vertebrate host. Japanese encephalitis 
viruses are believed to be maintained in populations of certain vertebrates, being transmitted 
among them by mosquitoes and other hematophagous arthropods, with man becoming 
tangentially infected when entering the environment in which these viruses are circulating. 
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The presence of antibodies in significant numbers of a particular species of bird or animal 
suggests that it may be an important natural reservoir or amplifier host (Buescher et al., 
1959b). An investigation in Chiang Mai Valley showed that each rainy season enormous 
numbers of the vector mosquitoes emerged from the flooded rice fields and irrigation ditches 
of the valley to feed on the numerous buffalo, cattle and pigs present in the rural areas. An 
analysis of the data suggested that pigs play a major role in the transmission of JEV in the 
Chiang Mai Valley (Grossman et al., 1974). Other studies also confirm that pigs are important 
hosts for amplification of virus dissemination in the epidemic region (Buscher & Scherer, 1959) 
and for maintenance of virus cycling in the endemic region (Simpson et al., 1970). 
It was also reported in other studies that many vertebrates were infected (SEATO Med Res 
Lab, 1969). One experimental infection study demonstrated that adults of a mammal, 
Menetes berdmorei, were susceptible to infection with JEV. Also, one species of rat, Rattus 
exulans, might be infected on occasion (William & Imlarp, 1972). 
Birds are considered as important hosts for JEV because Culex mosquitoes are readily fed on 
birds. It was demonstrated that 20 to 37 per cent of wild Japanese tree sparrows had 
neutralizing antibodies to JEV. Sparrows free of antibodies were inoculated with 10,000 
plaque-forming units of JEV. None of the birds became clinically ill. Virus could be detected 
in blood plasma during the first three days after inoculation but not thereafter (Yuill, 1969). 
It has been postulated that a certain species of bird (night heron) as well as migrant bird 
species might serve as a good vehicle to carry virus from one place to other place in a very 
long distance during the period of acute viremia (Scherer et al., 1959b). However, migrations 
of most bird species do not cover great distances such as from tropical to temperate areas in 
the few days that high titer primary viremia would persist. One may hypothesize 
transmission of infection to susceptible migrants at intermediate resting areas while in 
transit. Thus, birds moving in great distance may possibly serve as a source of vector 
infection. 
2.8 Reptile 
Beside mammals, it is quite interesting to note that two common species of house gecko 
lizards, Hemidactylus frenatus and Platyurus platyurus, are susceptible to JEV infection. It was 
shown that they developed viremia for six days with the concentration of virus in the blood 
high enough to be picked up by mosquitoes, Aedes aegypti (in the amount of 0.006- 0.06 ml) 
in which JEV could be detected by suckling mice inoculation and LLC-MK2 cell culture 
inoculation (Yuill et al., 1968; Yuill, 1969). It turns out that mosquitoes can be used as 
successful as needles and syringes for drawing blood from house gecko lizards for viremia 
determination, despite the fact that the mosquitoes usually draw less blood (0.006 – 0.06 ml) 
from each gecko than that is obtained with needle and syringe (0.05 to 0.1 ml). This finding 
is very useful in studying ecology of mosquito-borne viruses. Thus, the virological studies 
with JEV can be done, at daily intervals for one week when small size house gecko lizards 
are used as hosts for virus infection. Drawing blood from these very small (3 – 10 g) lizards 
with a syringe and 27-gauge needle invariably proved fatal. 
It has been demonstrated clearly by Grossman and his coworkers (Grossman et al., 1974) 
that a simple pattern of endemic in Thailand, year-round transmission of JEV between Culex 
mosquitoes and pigs seems sufficient to account for persistence of JEV in Chiang Mai Valley, 
and the appearance of human encephalitis cases. It was found that the human epidemics 






logarithmic increase in vector mosquito populations in April and early May. It coincided 
with the onset of the seasonal rains and was followed closely by larger numbers of infected 
mosquitoes as reflected by increased JEV transmission rates in sentinel pigs (Grossman et al., 
1974). Human epidemics probably resulted from greater exposure to these infected 
mosquitoes. The apparent resistance of bovines to infection (Johnsen et al., 1974) the slow 
rate of turnover in the bovine population, and bovine attractiveness to vector mosquitoes 
(Gould et al., 1974) indicate that bovines may actually suppress JEV infections, as has been 
suggested in India (Carey et al., 1969). 
Questions have been raised concerning low number of JEV cases during high number of 
vector population in certain endemic areas. Several factors are used to explain these facts, 
i.e., blood feeding on non-amplifier species of vertebrates, blood feeding on the immune 
portion of amplifier populations, inefficient transfer from infected mosquito to susceptible 
amplifier animal to susceptible mosquito. Not all susceptible amplifier hosts fed upon by 
infected Culex tritaeniorhynchus develop high enough viremia to infect other feeding 
mosquitoes, and high vector mortality between infectious blood meal and the second post-
infection oviposition. 
2.9 Ecology of mosquito vector 
Concerning the ecology of mosquito vector, some factors of greatest relevance to the 
abundance of JE vectors include the development of irrigation agriculture, e.g., utilization of 
rice fields and irrigation waste water by Culex tritaeniorhynchus, inadequate disposal of 
polluted water resulting from burgeoning urbanization and industrialization, e.g. Culex 
quinquefasciatus.  
In most areas in which JE in endemic Culex mosquitoes are now far more important than 
Aedes species in the transmission of the virus to humans, but species of the latter genus may 
be significant in the basic ecological cycle of JEV such as vectors to humans in some types of 
relatively undisturbed natural habitat. For example, although Culex tritaeniorhynchus and 
domestic pigs are now the most important hosts of JEV in Japan from the point of view of 
human infection, swine have been reared in significant numbers in Japan only since the 
opening of that country to contact with the outside world in 1853. The southeastern Soviet 
Union is the one area where the epidemiology of JEV has been studied in a setting not 
greatly changed by humans. Russian investigators consider three of Aedes (togoi, japonicus, 
and koreicus) as important vectors of JEV to humans in some types of habitat in this region 
(Petrischeva et al., 1963).  
A small number of closely related species of Culex mosquitoes serve as vectors, and many 
vertebrates are infected. Pigs in particular, are important hosts for amplification of virus 
dissemination in the epidemic region (Buescher and Scherer, 1959) and for maintenance of 
virus cycling in the endemic region (Simpson et al., 1970). Although the vectors are much 
more attracted to pigs than to man, it is presumed that the appearance of viremic pigs each 
spring in the temperate zone allows a large number of mosquitoes to become infected 
resulting in virus transmission to humans and encephalitis epidemic. 
3. Prevention and control 
Because of the shortage of appropriate form of specific treatment for Japanese encephalitis, 
control of the disease relies mainly on the control of the mosquito vector, on the early 
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identification of cases, and if possible, the isolation of cases from contact with vector 
mosquitoes. Vaccine against JEV is also available for high-risk group of people such as 
children in endemic area, military men, physicians and nurses. In addition, vaccine against 
JEV for pig vaccination is also available which is very useful in terms of reducing the 
number of susceptible amplifying hosts. 
There are three JEV vaccines that currently available for prevention of JEV. They are 
inactivated vaccine derived from mouse brains; cell culture-derived inactivated vaccine, and 
cell culture-derived live attenuated vaccines . Formalin-inactivated vaccine (JE-Vax) is the 
only vaccine currently in used internationally. It is produced from mouse brain tissue and is 
manufactured by the Research Foundation for Microbial Disease (BIKEN), Osaka, Japan, 
and also by the Government of Pharmaceutical Organization (GPO), Bangkok, Thailand. 
The GPO obtains the technical assistance from BIKEN and Japanese government to establish 
local production of inactivated mouse brain-derived vaccine from Nakayama and Beijing 
strains of JEV. The GPO has the capacity to produce only 40% of the national vaccine need. 
All of the rest are imported vaccine. Although it is effective, multiple-dose regimen is 
needed with the relatively high cost and problems with reactogenicity complicated its use. 
Inactivated and live-attenuated JE vaccine, prepared from JEV strain SA14-14-2 grown in 
primary hamster kidney (PHK) cells culture, have been developed and used only in China. 
Sporadic cases of viral encephalitis in Thailand have been noted in the northern part before 
1969. An epidemic transmission of JE was first recognized in 1969 when an outbreak leading 
to 685 cases occurred in the Chiang Mai valley. Yearly outbreaks numbering in the 
thousands of cases and hundreds of deaths recurred in the northern region and JE became a 
leading cause of mortality and disability in children. Hyperendemic JE transmission has 
subsequently spread within Thailand, and the adjacent area in Burma (Tsai, 2000). 
According to the continue public health impact of JE in Thailand, it has led to effort in 
childhood immunization and vaccine production in 1985. 
It was demonstrated by hemagglutination inhibition and neutralization assay that there are 
definitive antigenic differences among JEV Thai strain and between Thai strains and the 
standard subtypes, Nakayama and Beijing strains (Ali et al., 1995; Ali & Igarashi, 1997). 
Most of JEV isolated in Thailand are belonging to genotype I, while some belonging to 
genotype II, which strains Nakayama and Beijing are belonging to genotype III (Ali & 
Igarashi, 1997). The monovalent vaccine derived from JEV strain Nakayama or bivalent 
vaccine consisting of Nakayama and Beijing-1 strains provide 91% protective efficiency in 
either protocol in Thai children. These currently available vaccines are able to induce high 
levels of protective immunity against JEV belonging to heterologous genotypes. However, it 
is possible that vaccines produced from JEV strains isolated in Thailand may induce higher 
level of protective immunity against the locally circulating strains (Kurane & Takasaki, 
2000). 
3.1 Vaccine development 
The development of a vaccine that would induce rapid protection in people and animals is 
currently remained as an important issue. New generation of safe chimeric viruses that are 
unable to infect mosquitoes is currently ongoing in the development and preclinical studies. 
This would be a major step toward production of live-attenuated vaccine that is safer for the 
environment and would minimize the risk for vaccine-born outbreaks as reported in 1970s 






advantages including small dose is required for vaccination, a secretory IgA is produced 
against certain virus agent and the immune response last longer in recipients. This type of 
vaccine is an attractive one in vaccine development against several virus agents. An 
attenuation of virulence of the viruses is one of selected markers used for the development 
of live-attenuated vaccines. 
There is one live-attenuated JE vaccine currently available and being used in China. Live-
attenuated JE vaccine derived from SA14-14-2 strain has shown several advantages 
comparing to inactivated vaccine including lower dose in vaccination, low cost in vaccine 
production, and induction of long-lasting immune response in immunized children. This 
attenuated virus has small plaque phenotype. The potential of small plaque size mutants to 
be used as live-attenuated vaccine strains has been intensively investigated by several 
investigators. It has been shown that temperature sensitive (ts) mutants of dengue type 4 
virus and dengue 2 virus which have small plaque phenotype appeared to be attenuated in 
mice that may be useful for the development of a recombinant live attenuated vaccine of 
dengue virus (Blaney et al., 2002, Hanley et al., 2002, Huang et al., 2003). The small plaque 
mutants of other flaviviruses including West Nile virus (WNV) and tick-borne encephalitis 
virus (TBE), Murray Valley encephalitis virus (MVE), and JEV that are increase in cells 
infectivity and increase in affinity of glycosaminoglycan binding, have shown their 
virulence were attenuated in mouse model (Lee et al., 2004, Lee & Lobigs, 2002, Mandl et al., 
2001). In addition, almost all strains of JEV, which are small plaque size variants on BHK-21 
cells, except for JaGAr 01, are found to be correlated with the virulence attenuation of the 
viruses in mice (Kimura et al., 1973). Thus, it is quite interesting to find a small plaque size 
variant as a short cut to be used for the development of the vaccine. 
Live attenuated JE vaccine derived from SA14-14-2 strain has shown several advantages 
comparing to inactivated vaccine including lower dose in vaccination, low cost in vaccine 
production, and induction of long-lasting immune response in immunized children. This 
attenuated virus has small plaque phenotype. The potential of small plaque size mutants to 
be used as live-attenuated vaccine strains has been intensively investigated by several 
investigators. It has been shown that temperature sensitive (ts) mutants of dengue type 4 
virus and dengue 2 virus which have small plaque phenotype appeared to be attenuated in 
mice that may be useful for the development of a recombinant live attenuated vaccine of 
dengue virus (Blaney et al., 2002, Hanley et al., 2002, Huang et al., 2003). The small plaque 
mutants of other flaviviruses including West Nile virus (WNV) and tick-borne encephalitis 
virus (TBE), Murray Valley encephalitis virus (MVE), and JEV that are increase in cells 
infectivity and increase in affinity of glycosaminoglycan binding, have shown their 
virulence were attenuated in mouse model (Lee et al., 2004, Lee & Lobigs, 2002, Mandl et al., 
2001). In addition, almost all strains of JEV, which are small plaque size variants on BHK-21 
cells, except for JaGAr 01, are found to be correlated with the virulence attenuation of the 
viruses in mice (Kimura et al., 1973). Thus, it is quite interesting to find a small plaque size 
variant to use for the development of the vaccine. 
It has been shown that there is a good correlation between small plaque size and attenuation 
of viruses including several members of flavivirus, i.e., Dengue virus type 2, West Nile 
virus, Tick-borne encephalitis virus, and Murray Valley encephalitis virus (Tsai, 2000; 
Blaney et al., 2002; Hanley et al., 2002; Lee et al., 2004; Lee & Lobigs, 2002; Mandl et al., 2001; 
Huang et al., 2003). The vaccine strain, SA 14-14-2 of JEV, also has a small plaque size and 
grows quite well in PHK cells. This strain is currently used to produce live attenuated 
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vaccine in China (Tsai, 2000). It has been described that small plaque size phenotype is 
influenced by the burst size and short incubation. In addition, the sensitivity to interferon 
and growth conditions of viruses such as the nature of medium and temperature of 
incubation of infected cells may be involved in the production of small plaque size of the 
virus. It was documented that the small plaque variants of Sindbis virus were more 
susceptible to the action of interferon than a large plaque variant (Kimura et al., 1973).  
Serial passage the wild type virus in cell culture is a classical method for the selection of the 
attenuated strain of viruses. Small plaque size phenotype of the virus comparing to their 
parent strain are used as a marker for the selection of the virulence attenuation. Moreover, 
amino acid replacement in E protein is one of the markers to determine the phenotypic 
changes in neuro-virulence of the viruses as shown by several investigators. The most 
important is that the difference of amino acid changes in E protein of JEV may unique for 
each strain. However, these markers are useful to determine virulence attenuation for 
development of live-attenuated vaccine. To further understand the exact molecular 
mechanism of the small plaque mutants, the complete nucleotide sequence need to be 
done. 
Attempts have been made to select small plaque variants from the local strain of JEV in 
Thailand. It was demonstrated that the two suspected temperature-sensitive mutants of 
Japanese encephalitis virus strain KE-093 had an amino acid substitution, lysine for glutamic 
acid, in envelope protein at residue E-83 in the small plaque variants. The growth patterns 
and neurovirulence of these two small plaque variants of Japanese encephalitis virus in 
suckling mice remained the same as that of the parent strain, which suggested that small 
plaque phenotypes was not always associated with attenuation in vivo (Lorroengsil et al., 
2008). In contrast, it has been shown that JEV strain SA 14-14-2, the vaccine strain, could 
replicate in C6/36 cells better than the parent strain (Bhatt et al., 2000). TBE virus mutant 
(Oshima C1-1) that was selected by subculturing the parent strain (Oshima 5-10) in BHK-21 
cells was replicated better than the parent virus. The TBE virus mutant was attenuated for 
neuro-invasiveness in mouse model (Goto et al., 2003). This advantage is useful for the 
production of the live-attenuated vaccine using cell culture techniques. However, one 
precaution should be aware of is that the possibility of the vaccine strain that are replicating 
in the body of vaccinated people may serve as a source for the mosquito vector to feed on, 
and may revert back to the virulent form of the virus again. 
3.2 DNA vaccine 
The progresses in the development of DNA vaccine in Thailand are in the early phase of the 
development. Our group is also trying to use the most recent pathogenesis data to design a 
therapeutic vaccine that would reverse already established encephalitis and help clear the 
virus from the brain. 
Plasmid DNA-based vaccination strategies have become an active area of research over the 
past decade due to their potential to produce safer and cheaper vaccines. These vaccines 
could be delivered to recipients by intra-muscular (IM) injection or intra-dermal (ID) 
administration using a gene gun. IM inoculation of plasmid DNA vaccines to mice induces 
predominantly T helper 1 (Th1) immune responses, while T helper 2 (Th2) type immune 
responses are generated following the ID delivery. The isotypes of antibodies and the types 
of cytokines induced by the two methods differ and this could have bearing on the efficacy 






Attempts have been made to construct the plasmid DNA vaccine against JEV by trying to 
include JEV e gene in the plasmid DNA. It has been shown that these plasmids are capable 
of synthesizing JEV premembrane (prM) and E proteins, which have been evaluated in mice. 
Both forms of E protein however generated JEV neutralizing antibodies that provided 
significant protection to mice against lethal JEV challenge. 
The envelope (E) protein of JEV is also the interesting target for vaccine development. Since 
the E glycoprotein contains antigenic determinants for hemagglutination and neutralization. 
Mutations in the E gene are often responsible for significant alterations in the biological 
functions of the virus and may affect virulence (Richman et al., 2002).  It has been reported 
that there are the constructed recombinant DNA encoding full-length and sub-fragment E 
protein (Chen et al., 1999; Kaur & Sachdeva, 2002; Ashok & Rangarajan, 2002), C-terminal 
part and soluble form of E protein (Chia et al., 2001). These protein products induce 
neutralizing antibody and protective immunity in mice.  
E protein is known as an important protein, which plays roles in virion assembly, receptor 
binding, membrane fusion, and is a major target for neutralizing antibodies (Chambers et 
al., 1990). It has been noted that mutations in the E protein are often responsible for 
significant alterations in the biology of the virus and may affect virulence 
(Tiroumourougane et al., 2002; Richman et al., 2002; Burke & Monath, 2002; Chambers et al., 
1990; Heinz, 2003). Phenotype changes among flaviviruses have also been found to associate 
with amino acid alteration of E protein. It has been shown that seven amino acids in the 
virulent parent SA 14 have been substituted in attenuated vaccine clones, SA 14-14-2/PHK 
and SA 14-14-2/ PDK, when their genomes are compared. Four of them are located in E 
protein including E-138, E-176, E-315, and E-439. Three amino acids are located in non-
structural protein including NS2B-63, NS3-105, and NS4B-106. Several amino acids are also 
mutated, i.e., glutamic acid to lysine at E-138, isoleucine to valine at E-176, alanine to valine 
at E-315, lysine to arginine at E-439, glutamic acid to aspartic acid at NS2B-63, alanine to 
glycine at NS3-105, and isoleucine to valine at NS4B-106 (Ni et al., 1995). The attenuation 
concerning neuro-invasiveness in mice of the prototype JEV strains, Nakayama-O and an 
Indian 826309, was observed following six passages in Hela cells. Nine and eight amino 
acids substitutions were found in M and E protein of the attenuated Nakayama-O and an 
Indian 826309, respectively. The common one of amino acid substitution of these two 
attenuated viruses was alanine to valine at E-366 (Cao et al., 1995). It has been proposed that 
the mutation of the flavivirus strains that have been attenuated by serial passage do not 
share common genetic mutations that are associated with their phenotypes. However, there 
is a notable exception that the identical mutation from glutamic acid to lysine occurred at 
amino acid residue E-138 of the IC47 infectious clone-derived variants from JEV strain 
JaOArS982 and of the vaccine strain SA 14-14-2 (Kinney and Huang, 2001).  
E protein has been noted as the most important antigen in providing of protective immunity 
against JEV. Among three domains of E protein, neutralizing epitopes of domain III has 
been described. They were including of residues 308, 310, and 311 of louping ill virus; 384 
and 386 of TBE virus; 305 of yellow fever virus; 307, 383-389, and 333-351 of dengue viruses; 
306, 331, 333, 373-399, and 387 of JEV (Lin & Wu, 2003). Immunization with 27 amino acid of 
JEV E protein which is present on Johnson Grass Mosaic virus-like particles able to induce 
neutralizing antibodies without using adjuvant and protect mice from lethal challenge 
(Manishia & Vrati, 2003). This peptide, peptide A, contained residues 373 to 399 of JEV E 
protein was chosen for this study. Moreover, it has been shown by using complementary 
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structural modeling and site-directed mutagenesis of domain III of E protein of JEV in E. coli 
with monoclonal antibody (Mab) E3.3 that serine 331 and aspartic acid 332 have a potential 
to be neutralizing epitopes (Lin & Wu, 2003). Another peptide, peptide B, contained 
residues 325 to 333 was also selected. 
It has been shown that mouse immunized with virus-like particles (VLPs) presenting amino 
acid 373 to 399 from JEV E protein on domain III generated JEV neutralizing antibody 
without using adjuvant, and these mice were protected against a lethal JEV challenge 
(Manishia & Virati, 2003). It was demonstrated by site-directed mutagenesis that the 
functional domain at Ser331 and Asp332 on domain III of JEV E protein interacted with 
neutralizing monoclonal antibody (Mab) E3.3 (Lin & Wu, 2003). 
One of interest is the determination of the antigenic determinant of JEV from sub-fragment 
in domain III region of e gene. There is a possibility to insert two selected peptides that have 
been chopped into small overlapping peptides, synthesized, and linked with hepatitis B core 
peptide (HBc Ag), which is a B-cell epitope and recognized by mouse MHC. This HBc Ag 
may help JEV peptides in an activation of antibody response in immunized mice. The 
peptides, which show neutralizing activity against JEV, may serve as the antigenic epitopes 
of the virus. This antigenic epitopes will be useful in second-generation vaccine 
development against the local JEV in the future. 
It has been shown that serial passage of virus resulted in cell-adapted mutant that is 
attenuated in virulence in mice. Some of these mutants have changed in net positive 
charge of their proteins. They have high affinity for glycosaminoglycans (GAGs), which 
are highly-sulfate polysaccharides that are present almost ubiquitously on cell surfaces 
(Goto et al., 2003; Mandl et al., 2001). JEV replication in mice might require other viral or 
host cell-specific factors which do not present in BHK-21 cells infection. However, the 
mechanism by which cell-adapted flaviviruses undergo attenuation in vivo is not well 
understood.  
Protection against JEV is mainly antibody dependent. Virus neutralizing antibody alone is 
sufficient to impart protection. Previous report has been documented that formalin-
inactivated JEV vaccine does not induces CTLs but provides protection to vaccinees against 
JEV (Pan et al., 2001). Therefore, B cell epitopes on JEV E protein are important determinants 
of protection against virus infection. The whole E protein was not necessary for activating 
immune response but the small fragments of E protein were sufficient for eliciting the 
immune response and protect against JEV challenge (Lin & Wu, 2003; Kaur & Sachdeva, 
2002; Chia et al., 2001). 
As mentioned by previous reports that the whole protein was not necessary for activating 
immune responses, small protein fragments that contain antigenic epitopes are sufficient for 
eliciting the desired immune response. Peptide fragments of several pathogens, such as 
Brucella abortus, Trichinella spiralis and Plasmodium yoelii have potential to be used as vaccines 
(Moynihan & Howard, 2001). Peptide vaccines are easy to produce, biological stable at high 
temperature, no infectious agent present in the preparation and safe for human use. A major 
problem of peptide vaccine is their poor immunogenicity. Synthetic peptide need to be 
presented with the strong adjuvant or large carrier proteins to elicit good immune responses 
(Manishia & Virati, 2003). An envelope E gene of Japanese encephalitis virus genotype I, 
Thai strain KE-093 was successful cloning and heterologous expression in Escherichia coli 
Rosetta 2 strain (Witthajitsomboon et al., 2010). Attempts to develop DNA vaccine are going 






The rodent models have been used to evaluate vaccine candidates in pre-clinical studies, 
and nonhuman primates are usually the models of choice as they provide a robust system 
for evaluation of vaccine candidates. The Old World monkeys have predominantly been 
used in these types of studies with rhesus (Macaca mulatta) and cynomolgus (Macaca 
fascicularis) monkeys being most popularly used for evaluation of vaccine candidates 
against various infectious diseases, including those caused by Flaviviruses. It has been 
shown that the immunogenicity of premembrane-envelop proteins (pMEa and pMEs) 
delivered intramuscularly (IM) or intradermally (ID) in rhesus monkeys resulted in the 
DNA immunization induced protective levels of JEV neutralizing antibodies and 
generated robust memory that led to a rapid and sustained anamnestic response in 
monkeys sham challenged with mouse brain-grown, formaldehyde inactivated 
commercial vaccine. Several JEV proteins were evaluated in the DNA vaccine modality 
for their ability to induce protective immunity in the murine system. These include 
plasmids could express non-structural protein 1 (NS1), E or prM and E proteins of JEV. It 
was shown that variable degree of efficacy in murine model systems with plasmids 
expressing prM and E proteins conferring high degree of protection of mice against lethal 
JEV challenge, largely due to their ability to induce JEV neutralizing antibodies. Two 
plasmids could express prM protein along with full-length anchored E or truncated 
secretory E protein, while both plasmids induced JEV neutralizing antibodies in mice. To 
achieve this, efforts are underway to further enhance the immunogenicity of JE DNA 
candidate vaccine. 
4. Vector control 
4.1 Microbial insecticides 
An alternative approach for controlling Japanese encephalitis or any of mosquito-borne 
viruses is the reduction in mosquito vector population. It has been shown that the JEV can 
cause a long-lasting viremic phase in amplifying hosts. The virus can cause infection in pigs 
with the viremic phase last for 28 days, whereas the viremic phase in infected birds last for 
4-5 days with a very high virus titer, about 105 pfu/ml in a house sparrow(Yuill, 1969). 
These long lasting viremia in amplifying hosts provide ample opportunities for the 
susceptible mosquito vectors to become infected after feeding on them. Therefore, one way 
to block the transmission of the virus can be achieved by reducing the number of mosquito-
vector populations. This activity will lead to the reduction of new cases of infected patients 
in the endemic areas.  
The world Health Organization (WHO) has recommended utilization of Bacillus 
thuringiensis var. israelensis (Bti) as an agent for biological control of mosquitoes since 1978 
(Arata et al., 1978). The recommendation was based on the facts that Bti produces 
proteinaceous parasporal crystals during sporulation. These crystals are composed of 
multiple proteins ranging from 26 to 135 kilodaltons (kDa) in size with act as a protoxin (135 
kDa). The crystals are lethal to larval mosquitoes (Goldberg & Margalit, 1977), and to 
blackflies (Undeen & Nagel, 1978). No effect is observed on non-target aquatic insects, fish, 
or frog larvae (Garcia & Goldberg, 1978). It has been shown that several chemicals can 
persist for a long time in the environment, they are hazardous to humans. Thus, the 
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4.1.1 Bacillus thuringiensis var. israelensis 
One of the most successful insect pathogens used for insect control is the bacterium Bacillus 
thuringiensis subspecies israelensis, which presently is ~ 2% of the total insecticidal market. 
Bti is almost exclusively active against larval stages of different mosquito species, i.e., Aedes 
aegypti, Culex quinquefascatus, Culex gelidus, and Culex tritaeniorhynchus and kills the insect by 
disruption of the midgut tissue followed by septicemia caused probably not only by Bacillus 
thuringiensis but probably also by other bacterial species (Raymond et al., 2010). The action 
of Bacillus thuringiensis relies mainly on insecticidal toxins that are active during the 
pathogenic process. In addition, these bacteria also produce an array of virulence factors 
that contribute to insect killing (Bravo et al., 2005). Upon sporulation, Bacillus thuringiensis 
produces insecticidal crystal inclusions that are formed by a variety of insecticidal proteins 
called Cry or Cyt toxins. These toxins show a highly selective spectrum of activity killing a 
narrow range of insect species. The Cry and Cyt toxins belong to a class of bacterial toxins 
known as pore forming toxins (PFT) that are secreted as water-soluble proteins and 
subsequent undergo conformational changes in order to insert into the membrane of their 
hosts. Despite the limited use of Bacillus thuringiensis products as spray-able insecticides, 
Cry toxins have been introduced into transgenic crops providing a more targeted and 
effective way to control insect pests in agriculture. Concomitantly, this approach has 
resulted in significant reduction in the use of chemical insecticides in places where this 
technology has been embraced. 
4.1.2 Bacllus sphaericus 
One promising agent that may be used as microbial insecticides is a spore-forming bacillus, 
Bacillus sphaericus. This bacterium is an aerobic, gram-positive, spore-forming bacillus, 
which is also widespread in soil and aquatic environments. Some strains produce a toxin 
which is lethal when ingested by filter-feeding mosquito larvae. Kellen and his colleagues 
described the isolation of a larvicidal Bacillus sphaericus strain K from moribund larvae in the 
U.S. in 1965 (Kellen et al., 1965). A more pathogenic strain, strain SSII-1, was later isolated by 
Singer (Singer, 1973) from infected larvae collected in India. Subsequently, more highly 
toxic strains were isolated from around the world, among which are strain 1593 from 
Indonesia (Singer & Murphy, 1976), strain 2297 from Sri Lanka (Wickremesinghe & 
Mendis, 1980), and strain 2362 from Nigeria (Weiser, 1984). The potency and specificity of 
the Bacillus sphaericus toxins make them promising agents for biological control of 
mosquito pests. 
Comparison of the larvicidal toxins from Bacillus sphaericus strains SSII-1, 1593 and 2362 
revealed several important differences (Myers et al., 1979). Bacillus sphaericus yielded better 
results against larvae of Culex quinquefasciatus and Anopheles minimus than that of Aedes 
aegypti larvae (Pantuwatana, 1989). 
Attempts have been made to produce several formulations of microbial insecticides, Bacillus 
sphaericus, and Bacillus thuringiensis var. israelensis (Bti). Microbial insecticides have been 
proposed as substitutes for chemicals because they have a narrow and specific spectrum of 
activities that enable them to kill only certain insect species. But their use is limited since 
most microbes show a narrow spectrum of activity that enables them to kill only certain 
insect species. Moreover, they have low environmental persistence and they require precise 
application practices, since many of these pathogens are specific to young insect larval 






The slow-release formulations of products made from microbial insecticides, i.e., Bacillus 
sphaericus, and Bacillus thuringiensis var. israelensis, have been used in field trials against 
certain species of mosquito larvae especially Culex quiquefasciatus, with a satisfactory result. 
However, it is very difficult to apply the aforementioned formulations of microbial 
insecticides’ products in the breeding places of the mosquito vectors, because the mosquito 
larvae of Culex species are filter feeder, which feed on the surface of the water. All larvae of 
the mosquito vector species are found in polluted water. It has been shown that the 
effectiveness of microbial insecticides’ products is not reached a satisfactory result. Efforts 
on the development of microbial insecticides for biological control of mosquito vector are 
underway in parallel with the recent advances in biotechnology. 
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